Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. Borisov, T. Ivanushkina, N. Litvinova, Y. Garmash (Moscow, Russian Federation). Linezolid in the treatment of multi- and extensively drug-resistance tuberculosis. Eur Respir J 2011; 38: Suppl. 55, 4400

Member's Comments

No comment yet.

Related content which might interest you: Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis Source: Eur Respir J 2016; 47: 564-574 Year: 2016 Linezolid in multidrug-resistant tuberculosis treatment Source: Eur Respir J 2004; 24: Suppl. 48, 485s Year: 2004 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Source: Eur Respir J 2012; 39: 956-962 Year: 2012 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009 Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016 Mefloquine as a potential drug against multidrug-resistant tuberculosis Source: Eur Respir J 2015; 46: 1503-1505 Year: 2015 Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis Source: Eur Respir J 2011; 38: 730-733 Year: 2011 First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline Source: Eur Respir J 2016; 48: 935-938 Year: 2016 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis Source: Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020 Year: 2021 Clinical and operational value of the extensively drug-resistant tuberculosis definition Source: Eur Respir J 2007; 30: 623-626 Year: 2007 Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Early access to bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis Source: Eur Respir J, 54 (1) 1802208; 10.1183/13993003.02208-2018 Year: 2019 Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine Source: Eur Respir J 2016; 48: 1527-1529 Year: 2016 Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine Source: Eur Respir J 2016; 48: 1526-1527 Year: 2016 Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017 Year: 2017 Treatment options for patients with multidrug-resistant or extensively drug-resistant tuberculosis Source: Annual Congress 2009 - Priorities in tuberculosis research Year: 2009 Treating extensively drug resistant tuberculosis (XDR-TB) in India Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis? Source: Eur Respir J, 55 (2) 1901908; 10.1183/13993003.01908-2019 Year: 2020